The effect of antibacterial agents on the production of nitric oxide induced by lipopolysaccharide in mice
Hampartsoum Barsoumian, Fadi El-Rami, Alexander M. Abdelnoor
DOI: 10.4236/abb.2010.12010   PDF    HTML     5,551 Downloads   10,315 Views   Citations


Some antibacterial agents have been shown to neutralize the biological properties of bacterial lipopolysaccharide (LPS). The aim of this study was to eluci- date the role of gentamicin, tobramycin, imipenem, tigecycline, and isoniazid in affecting the production of nitric oxide (NO) induced by LPS in mice. Groups of mice were injected intraperitoneally with LPS alone, antibacterial agent alone, or LPS in combination with an antibacterial agent. Serum NO levels were determined at 1, 3, 6 and 9 hours post-injection using the Griess reagent method. Thin layer chroma- tography was performed to determine if antibacterial agent—LPS interaction had occurred. All the antibacterial agents suppressed NO production. More- over, LPS-induced production of NO was suppressed by all the antibacterial agents, tobramycin and tigecycline being the most effective at 9 hours post-injection. Blocking of any of the stages leading to NO production by the antibacterial agents is suggested. Moreover, thin layer chromatograms obtained are suggestive of LPS-antibacterial agent interactions.

Share and Cite:

Barsoumian, H. , El-Rami, F. and Abdelnoor, A. (2010) The effect of antibacterial agents on the production of nitric oxide induced by lipopolysaccharide in mice. Advances in Bioscience and Biotechnology, 1, 61-67. doi: 10.4236/abb.2010.12010.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Lepper, P.M., Held, T.K., Schneider, E.M., Bolke, E., Gerlach, H. and Trautmann, M. (2002) Clinical implications of antibiotic-induced endotoxin release in septic shock. Intensive Care Medicine, 28(7), 824-833.
[2] Parratt, J.R. (1998) Nitric oxide in sepsis and endotoxaemia. Journal of Antimicrobial Chemotherapy, 41(1), 31-39.
[3] Hegemann, F. and Lessmann, H. (1958) Nature of the pyrogen-neutralizing factor in human blood. V. occurrence of the endotoxinneutralizing serum factor in various animal species. Zeitschrift Für Immunitatsforschung Und Experimentelle Therapie, 115(5), 391-401.
[4] Stauch, J.E. and Johnson, A.G. (1959) The alteration of bacterial endotoxins by human and rabbit serum. Journal of Immunology, 82, 252-263.
[5] Abdelnoor, A.M., Harvie N.R. and Johnson A.G. (1982) Neutralization of bacteria-and endotoxin-induced hypotension by lipoprotein-free human serum. Infection and Immunity, 38(1), 157-161.
[6] Cherkin, A. (1975) Destruction of bacterial endotoxin pyrogenicity by hydrogen peroxide. Immunochemistry, 12(6-7), 625-627.
[7] Noll, H. and Braude, A.I. (1961) Preparation and biological properties of a chemically modified escherichia coli endotoxin of high immunogenic potency and low toxicity. Journal of Clinical Investigation, 40(11), 1935-1951.
[8] Nowotny, A. (1963) Endotoxoid preparations. Nature, 197(4868), 721-722.
[9] Ribi, E., Anacker, R.L., Brown, R., Haskins, W.T., Malmgren, B., Milner, K.C., et al. (1966) Reaction of endotoxin and surfactants. I. physical and biological properties of endotoxin treated with sodium deoxycholate. Journal of Bacteriology, 92(5), 1493-1509.
[10] Tarmina, D.F., Milner, K.C., Ribi, E. and Rudbach, J.A. (1968) Reaction of endotoxin and surfactants. II. Immunologic properties of endotoxins treated with sodium deoxycholate. Journal of Immunology, 100(2), 444-450.
[11] Keene, W.R., Landy, M. and Shear, M.J. (1961) Inactiva- tion of endotoxin by a humoral component. VII. enzymatic degradation of endotoxin by blood plasma. Journal of Clinical Investigation, 40, 302-310.
[12] Yoshioka, M. and Johnson, A.G. (1962) Characteristics of endotoxin altering fractions derived from normal human serum. Journal of Immunology, 89, 326-335.
[13] Al-Shami, A.K., Itani, L.Y., Skaff, N.N., Haddad, E.K., Abdelnoor, A.M. (1995) Effects of acetyl salicylic acid, tobramycin and vancomycin on some biological activities of endotoxin. EOS Rivista di Immunologia ed Immunofarmacologia, 15, 71-75.
[14] David, S.A., Silverstein, R., Amura, C.R., Kielian, T. and Morrison, D.C. (1999) Lipopolyamines: Novel antiendotoxin compounds that reduce mortality in experimental sepsis caused by gram-negative bacteria. Antimicrobial Agents & Chemotherapy, 43(4), 912-919.
[15] Moore, R.A., Bates, N.C. and Hancock, R.E. (1986) Interaction of polycationic antibiotics with pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrobial Agents & Chemotherapy, 29(3), 496-500.
[16] Jerala, R. and Porro, M. (2004) Endotoxin neutralizing peptides. Current Topics in Medicinal Chemistry, 4(11), 1173-1184.
[17] Zorko, M. and Jerala, R. (2008) Alexidine and chlorhexidine bind to lipopolysaccharide and lipoteichoic acid and prevent cell activation by antibiotics. Journal of Antimicrobial Chemotherapy, 62(4), 730-737.
[18] Buttke, T.M. and Ingram, L.O. (1975) Comparison of lipopolysaccharides from agmenellum quadruplicatum to escherichia coli and salmonella typhimurium by using thin-layer chromatography. Journal of Bacteriology, 124(3), 1566-1573.
[19] Terao, H., Asano, K., Kanai, K., Kyo, Y., Watanabe, S., Hisamitsu, T., et al. (2003) Suppressive activity of macrolide antibiotics on nitric oxide production by lipopolysaccharide stimulation in mice. Mediators of Inflamma- tion, 12(4), 195-202.
[20] Moreira, A.L., Wang, J., Sarno, E.N. and Kaplan, G. (1997) Thalidomide protects mice against LPS-induced shock. Brazilian Journal of Medical & Biological Research, 30(10), 1199-1207.
[21] Kusser, W.C. and Ishiguro, E.E. (1988) Effects of aminoglycosides and spectinomycin on the synthesis and release of lipopolysaccharide by escherichia coli. Antimicrobial Agents & Chemotherapy, 32(8), 1247-1250.
[22] Sugiyama, K., Shirai, R., Mukae, H., Ishimoto, H., Nagata, T., Sakamoto, N., et al. (2007) Differing effects of clarithromycin and azithromycin on cytokine production by murine dendritic cells. Clinical & Experimental Immunology, 147(3), 540-546.
[23] Kaushik V., Beduya D., Kalampokis I., Kohlhoff, S., O Joks R., G Durkin H. and Nowakowski M. (2007) Tetracyclines tigecycline and doxycycline inhibit LPS-induced nitric oxide production by RAW 264.7 murine macro- phages. Journal of Immunology, 178, (101)1-7.
[24] Cazalis, J., Bodet, C., Gagnon, G. and Grenier, D. (2008) Doxycycline reduces lipopolysaccharide-induced inflammatory mediator secretion in macrophage and ex vivo human whole blood models. Journal of Periodontology, 79(9), 1762-1768.
[25] Yang, L.P., Zhu, X.A. and Tso, M.O. (2007) Minocycline and sulforaphane inhibited lipopolysaccharide-mediated retinal microglial activation. Molecular Vision, 13, 1083- 1093.
[26] Henry, C.J., Huang, Y., Wynne, A., Hanke, M., Himler, J., Bailey, M.T., et al. (2008) Minocycline attenuates lipopolysaccharide (LPS)-induced neuroinflammation, sickness behavior, and anhedonia. Journal of Neuroinflammation, 5, (15)1-14.
[27] Eswarappa, S.M., Basu, N., Joy, O. and Chakravortty, D. (2008) Folimycin (concanamycin A) inhibits LPS-induced nitric oxide production and reduces surface localization of TLR4 in murine macrophages. Innate Immunity, 14(1), 13-24.
[28] He, H., Genovese, K.J., Nisbet, D.J. and Kogut, M.H. (2006) Involvement of phosphatidylinositol-phospholipase C in immune response to salmonella lipopolysacharide in chicken macrophage cells (HD11). International Immunopharmacology, 6(12), 1780-1787.
[29] Yamamoto, M., Sato, S., Hemmi, H., Sanjo, H., Uematsu, S., Kaisho, T., et al. (2002) Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature, 420, 324-329.
[30] Bagchi, A., Herrup, E.A., Warren, H.S., Trigilio, J., Shin, H.S., Valentine, C., et al. (2007) MyD88-dependent and MyD88-independent pathways in synergy, priming, and tolerance between TLR agonists. Journal of Immunology, 178, 1164-1171.
[31] Rabel, F. (2009) Reviving Thin Layer Chromatography. Chromatography Techniques.
[32] Timmins, G.S. and Deretic, V. (2006) Mechanisms of action of isoniazid. Molecular Microbiology, 62(5), 1220-1227.
[33] Rehan, V.K., Dargan-Batra, S.K., Wang, Y., Cerny, L., Sakurai, R., Santos, J., et al. (2007) A paradoxical temporal response of the PTHrP/PPARgamma signaling pathway to lipopolysaccharide in an in vitro model of the developing rat lung. American Journal of Physiology. Lung Cellular and Molecular Physiology, 293(1), 182-190.
[34] Behling, U.H. and Nowotny, A. (1977) Immune adjuvancy of lipopolysaccharide and a nontoxic hydrolytic product demonstrating oscillating effects with time. Journal of Immunology, 118, 1905-1907.
[35] Haas, G.P., Johnson, A.G. and Nowotny, A. (1978) Suppression of the immune response in C3H/HeJ mice by protein-free lipopolysaccharides. Journal of Experimental Medicine, 148(4), 1081-1086.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.